For example, in glioblastoma, the receptor tyrosine kinase signalling pathway can be altered by disruption of the EGFR oncogene, either via gene fusion (EGFRvIII fusion [144]) or gene dosage increase (EGFR amplification [145, 146]), caused by either simple or complex SVs [147, 148]. This evidence concerns the gene EGFR and glioblastoma.